Immunocore and Genentech enter strategic alliance to develop ImmTACs for multiple cancer targets

PRESS RELEASE – IMMUNOCORE LIMITED

 

(Oxford, UK, 27 June 2013) Immunocore Limited, the Oxford-based biotechnology company developing novel biological drugs known as ImmTACs to treat cancer and viral disease, today announced that it has entered into a research collaboration and licensing agreement with Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), for the discovery and development of multiple novel cancer targets using Immunocore's ImmTAC technology.

Under the terms of the agreement, Immunocore will receive an initiation fee of between $10 and $20 million per programme and is eligible to receive in excess of $300 million in development and commercial milestone payments for each target programme and significant tiered royalties.

Immunocore has created a world-leading platform of bi-specific biological drugs, called ImmTACs, which exploit the power of T Cell Receptors (TCRs) to recognise intracellular changes that occur during cancer or viral infection.  This unique recognition ability of TCRs sets them apart from traditional antibody-based therapies that can only recognise changes on the surface of cells, and provides, for the first time, the ability to develop extremely potent targeted therapies for cancers that are currently poorly served.  A particular feature is that the ImmTACs can be directed to target and destroy only the cancerous cells, avoiding damage to healthy cells. 

James Noble, Chief Executive Officer of Immunocore, commented: "We are very pleased to have Genentech, a recognized leader in oncology, on board as our first major partner to discover, develop and commercialise ImmTAC therapies against multiple cancer targets."

James Sabry, Senior Vice President of Genentech Partnering, said: "We believe Immunocore is the leading company in T Cell receptor biology and drug development and an excellent partner for Genentech in this area.  We are delighted to have initiated this significant partnership with them. We hope this collaboration will lead to breakthrough therapies for cancer patients with unmet medical needs."

Bent Jakobsen, Chief Scientific Officer and founder of Immunocore, added: "Our collaboration with Genentech generating ImmTACs against these novel targets allows us jointly to explore the true potential of the technology. We have established a robust and reproducible platform and we look forward to see ImmTACs addressing some of the major challenges in cancer therapy."

-ENDS-


 

Contact

Margaret Henry

PR Consultant

Immunocore Ltd, UK

T: + 44 (0) 1865 261491

M: + 44 (0) 7771 377363

E: [email protected]

Suggested Articles

The deal, which features an additional $2 billion in milestones, will give Bayer control of an AAV platform and a clinical-phase pipeline.

The result, which beats the 35% reported by KRAS rival Amgen, sets Mirati up to file for FDA approval of the drug in the second half of next year.

Scorpion is working on precision oncology 2.0, including making better drugs for known targets, hitting undruggable targets and discovering new ones.